4 assets in Ganglioglioma

Therapeutic assets addressing Ganglioglioma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dabrafenib Ganglioglioma	Novartis Pharmaceuticals	P4	BB (65)
Trametinib Ganglioglioma	Novartis Pharmaceuticals	P4	BB (65)
Cyclophosphamide Ganglioglioma	Dana-Farber Cancer Institute	P1	CC (43)
Rqnestin Ganglioglioma	Dana-Farber Cancer Institute	P1	CC (43)